↓ Skip to main content

Cytidinediphosphocholine (CDP-choline) for cognitive and behavioural disturbances associated with chronic cerebral disorders in the elderly

Overview of attention for article published in Cochrane database of systematic reviews, April 2005
Altmetric Badge

About this Attention Score

  • In the top 25% of all research outputs scored by Altmetric
  • High Attention Score compared to outputs of the same age (94th percentile)
  • Good Attention Score compared to outputs of the same age and source (71st percentile)

Mentioned by

blogs
2 blogs
twitter
4 tweeters
q&a
1 Q&A thread

Citations

dimensions_citation
97 Dimensions

Readers on

mendeley
168 Mendeley
You are seeing a free-to-access but limited selection of the activity Altmetric has collected about this research output. Click here to find out more.
Title
Cytidinediphosphocholine (CDP-choline) for cognitive and behavioural disturbances associated with chronic cerebral disorders in the elderly
Published in
Cochrane database of systematic reviews, April 2005
DOI 10.1002/14651858.cd000269.pub3
Pubmed ID
Authors

Mario Fioravanti, Motokazu Yanagi

Abstract

CDP-choline (cytidine 5'-diphosphocholine) is a precursor essential for the synthesis of phosphatidylcholine, one of the cell membrane components that is degraded during cerebral ischaemia to free fatty acids and free radicals. Animal studies suggest that CDP-choline may protect cell membranes by accelerating resynthesis of phospholipids. CDP-choline may also attenuate the progression of ischaemic cell damage by suppressing the release of free fatty acids. CDP-choline is the endogenous compound normally produced by the organism. When the same substance is introduced as a drug it can be called citicoline.CDP-choline is mainly used in the treatment of disorders of a cerebrovascular nature. The many years of its presence in the clinical field have caused an evolution in dosage, method of administration, and selection criteria of patients to whom the treatments were given. Modalities of the clinical studies, including length of observation, severity of disturbance, and methodology of evaluation of the results were also heterogeneous. In spite of uncertainties about its efficacy due to these complexities, CDP-choline is a frequently prescribed drug for cognitive impairment in several European countries, especially when the clinical picture is predominantly one of cerebrovascular disease, hence the need for this review. Due to its effects on the adrenergic and dopaminergic activity of the CNS, CDP-choline has also been used as an adjuvant in the treatment of Parkinson's disease.

Twitter Demographics

The data shown below were collected from the profiles of 4 tweeters who shared this research output. Click here to find out more about how the information was compiled.

Mendeley readers

The data shown below were compiled from readership statistics for 168 Mendeley readers of this research output. Click here to see the associated Mendeley record.

Geographical breakdown

Country Count As %
United States 3 2%
Canada 1 <1%
United Kingdom 1 <1%
Mexico 1 <1%
Japan 1 <1%
South Africa 1 <1%
Unknown 160 95%

Demographic breakdown

Readers by professional status Count As %
Student > Master 27 16%
Researcher 24 14%
Student > Ph. D. Student 19 11%
Student > Bachelor 17 10%
Other 14 8%
Other 45 27%
Unknown 22 13%
Readers by discipline Count As %
Medicine and Dentistry 49 29%
Psychology 22 13%
Agricultural and Biological Sciences 15 9%
Neuroscience 10 6%
Nursing and Health Professions 9 5%
Other 32 19%
Unknown 31 18%

Attention Score in Context

This research output has an Altmetric Attention Score of 17. This is our high-level measure of the quality and quantity of online attention that it has received. This Attention Score, as well as the ranking and number of research outputs shown below, was calculated when the research output was last mentioned on 07 November 2016.
All research outputs
#800,304
of 12,527,093 outputs
Outputs from Cochrane database of systematic reviews
#2,387
of 8,923 outputs
Outputs of similar age
#11,594
of 213,494 outputs
Outputs of similar age from Cochrane database of systematic reviews
#137
of 484 outputs
Altmetric has tracked 12,527,093 research outputs across all sources so far. Compared to these this one has done particularly well and is in the 93rd percentile: it's in the top 10% of all research outputs ever tracked by Altmetric.
So far Altmetric has tracked 8,923 research outputs from this source. They typically receive a lot more attention than average, with a mean Attention Score of 21.2. This one has gotten more attention than average, scoring higher than 74% of its peers.
Older research outputs will score higher simply because they've had more time to accumulate mentions. To account for age we can compare this Altmetric Attention Score to the 213,494 tracked outputs that were published within six weeks on either side of this one in any source. This one has done particularly well, scoring higher than 94% of its contemporaries.
We're also able to compare this research output to 484 others from the same source and published within six weeks on either side of this one. This one has gotten more attention than average, scoring higher than 71% of its contemporaries.